智通财经网·2025-08-22 09:38Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates for oxytocin injection and octreotide acetate injection from the Philippines Food and Drug Administration, allowing the company to sell these products in the Philippine market, which positively impacts its overseas market expansion and accumulates valuable experience [1]. Group 1 - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical Pharmaceutical Co., Ltd., produced the approved drugs, indicating the company's capability in pharmaceutical manufacturing [1]. - The approved oxytocin injection (1mL:10 units) and octreotide acetate injection (1mL:0.1mg) signify the company's compliance with international regulatory standards [1]. - The registration marks a significant step for the company in expanding its presence in the Southeast Asian pharmaceutical market [1].